On November 20th, Southern Finance and Economics reported that Innolux (NASDAQ: ILMN) announced today that it will launch a new version of its flagship cancer research detection product, TruSight Oncology 500 v2 (TSO 500 v2), to achieve genomic panoramic variation analysis (CGP). The test is currently under development and is scheduled for global release in mid-2025. TSO 500 v2 will be able to evaluate all mutation categories and immune tumor biomarkers of hundreds of genes in a single detection, to assist in research on treatment selection. (21st Century Business Herald)